{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T06:40:55Z","timestamp":1792219255213,"version":"4.4.0"},"reference-count":23,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["23K14428"],"award-info":[{"award-number":["23K14428"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2026,11]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To characterize cancer treatment during pregnancy and maternal and infant outcomes among women with cancer identified during pregnancy in Japan.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this descriptive cohort study, we used mother\u2010infant linkage data from the JMDC claims database from 2005 to 2024. Live\u2010birth pregnancies were considered eligible when a malignant neoplasm (ICD\u201010 C00\u2013C97) was recorded between the estimated pregnancy onset and delivery. Exposure was defined as at least one anticancer agent prescribed between the diagnosis and delivery; surgery and radiation therapy were also identified. The outcomes were preterm delivery and major congenital malformation at 6\u2009months of age. Pregnancies without a diagnosis of malignant neoplasms constituted the internal reference group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of the 500 pregnancies with cancer identified during pregnancy, 16 (3.2%) had an anticancer agent prescribed, 46 (9.2%) underwent surgery for malignant tumors, and none underwent radiation therapy. Cancer was identified in the second trimester in 10 of the 16 pregnancies with exposure (62.5%) and in 128 of the 484 pregnancies without exposure (26.4%). All eight pregnancies with breast cancer received an anthracycline with cyclophosphamide. The frequencies in the reference group (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009236\u2009002), without exposure, and with exposure were 12.0%, 20.9%, and 37.5% for preterm delivery and 6.1%, 9.1%, and 12.5% for major congenital malformation, respectively.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Cancer identified during pregnancy was treated in a minority of women, and anticancer agents were most often prescribed when cancer was identified in the second trimester. Outcomes were recorded more often in pregnancies with cancer but cannot be attributed to anticancer agent exposure.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/pds.70508","type":"journal-article","created":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T05:50:48Z","timestamp":1792216248000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cancer Treatment During Pregnancy and Maternal and Infant Outcomes: A Descriptive Cohort Study Using a Japanese Claims Database"],"prefix":"10.1002","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3846-0435","authenticated-orcid":false,"given":"Masami","family":"Tsuchiya","sequence":"first","affiliation":[{"name":"Division of Drug Informatics Keio University Faculty of Pharmacy  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0901-368X","authenticated-orcid":false,"given":"Tomofumi","family":"Ishikawa","sequence":"additional","affiliation":[{"name":"Laboratory of Biomolecule and Pathophysiological Chemistry, Graduate School of Pharmaceutical Sciences Tohoku University  Sendai Miyagi Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9086-6999","authenticated-orcid":false,"given":"Takamasa","family":"Sakai","sequence":"additional","affiliation":[{"name":"Drug Informatics, Faculty of Pharmacy Meijo University  Nagoya Aichi Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4596-5418","authenticated-orcid":false,"given":"Satoko","family":"Hori","sequence":"additional","affiliation":[{"name":"Division of Drug Informatics Keio University Faculty of Pharmacy  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3674-1674","authenticated-orcid":false,"given":"Taku","family":"Obara","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences Tohoku University Hospital  Sendai Miyagi Japan"},{"name":"Division of Preventive Medicine and Epidemiology Tohoku University Tohoku Medical Megabank Organization  Sendai Miyagi Japan"},{"name":"Department of Clinical Epidemiology, Graduate School of Medicine Tohoku University  Sendai Miyagi Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,10,16]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt199"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijgo.70258"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(18)30059\u20107"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocpiqo.2024.02.002"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharma2010002"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4444"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/bdr2.2247"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/jgf2.422"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S429246"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k3532"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12061356"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1089\/jwh.2018.6962"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/aog.0b013e31826d60c5"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3446"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2019.07.014"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.5244"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.preghy.2023.01.001"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2010.09.010"},{"key":"e_1_2_12_20_1","volume-title":"Clinical Guidelines for Pregnancy, Childbirth, and Reproductive Medicine in Breast Cancer Patients","author":"Japanese Society of Fertility Preservation","year":"2021"},{"key":"e_1_2_12_21_1","volume-title":"Clinical Guidelines for Pregnancy, Childbirth, and Reproductive Medicine in Breast Cancer Patients","author":"Japanese Society of Fertility Preservation","year":"2026"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijgc.2025.101975"},{"key":"e_1_2_12_23_1","unstructured":"Japanese Society of Hematology \u201cClinical Practice Guidelines for hematopoietic Malignancies 2024 revision. version 3.1 \u201d2024 accessed August 7 2026 https:\/\/www.jshem.or.jp\/gui\u2010hemali\/."},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2024.10.022"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.70508","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/pds.70508","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.70508","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T05:50:49Z","timestamp":1792216249000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.70508"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,16]]},"references-count":23,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["10.1002\/pds.70508"],"URL":"https:\/\/doi.org\/10.1002\/pds.70508","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"value":"1053-8569","type":"print"},{"value":"1099-1557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,16]]},"assertion":[{"value":"2026-08-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70508"}}